NCT05069298

Effect of Silibinin(A) as a Potential Anti-obesity Agent

Effect of Milk Thistle Derivative Silibinin(A) as a Potential Anti-obesity Agent

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Universidad Católica San Antonio de Murcia · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

Our preliminary reports have found in silico and in vitro that the milk thistle derivative Silibinin(A) is able to inhibit pancreatic lipase, in a similar way that the classical anti-obesity drug orlistat. Therefore, the investigators want to carry out the present trial in order to confirm that Silibinin(A) is able to in vivo inhibit pancreatic lipase, which will reduce the fat absorption and therefore will decrease the amount of energy from food intake. Considering that milk thistle has been extensively studied in humans as liver-protector, the investigators consider that the use of human subjects will be of great interest to accelerate the employment of this compound to improve the effectiveness of dietary treatment in overweight/obese subjects.

Conditions

• Overweight and Obesity
• Hypercholesterolemia
• Hypertriglyceridemia

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Silibinin A	The compound will be administered following a 300 mg / 3 day schedule, before each main meal.

Timeline

• Start date: 2023-01-12
• Primary completion: 2023-12-01
• Completion: 2023-12-21
• First posted: 2021-10-06
• Last updated: 2023-06-23

Locations

1 site across 1 country: Spain